Institut für Röntgendiagnostik, Universtitätsklinikum Regensburg, Regensburg, Germany.
Institut für Psychologie, Universität Kassel, Kassel, Germany.
Clin Hemorheol Microcirc. 2021;79(1):73-80. doi: 10.3233/CH-219118.
Liver function is one of the most important parameters for the outcome of transarterial chemoembolization (TACE). The liver maximum capacity (LiMAx) test is a bedside test that provides a real-time option for liver function testing. The objective of this pilot study was to investigate the suitability of the LiMAX test for predicting the TACE outcome.
20 patients with intermediate-stage hepatocellular carcinoma (HCC) received a LiMAx test 24 h pre and post TACE. In addition, laboratory values were collected to determine liver function and model for endstage liver disease (MELD) scores. The success of TACE was assessed 6 weeks post intervention by morphological imaging tests using modified response evaluation criteria in solid tumors (mRECIST).
Patients with an objective response (OR = CR + PR) according to mRECIST post TACE had significantly higher values in the pre-interventional LiMAx test than patients with a non-OR (PD or SD) post TACE (r(14) = 0.62, p = 0.01). Higher pre-interventional LiMAx values therefore indicate OR. Patients with a disease control (DC = CR + PR + SD) according to mRECIST post TACE had significantly higher values in the pre-interventional LiMAx test than patients with a non-DC (PD) post TACE (r(14) = 0.65, p = 0.01). Higher pre-interventional LiMAx values therefore indicate DC. The point biserial correlations of LiMAx values pre and post TACE with the outcome OR or DC were descriptively stronger than those of MELD with OR or DC. This suggests that the LiMAx test correlates better with the treatment response than the MELD score.
For the first time, we were able to show in our study that patients who are scheduled for TACE could benefit from a LiMAx test to be able to estimate the benefit of TACE. The higher the pre-interventional LiMAx values, the higher the benefit of TACE. On the other hand, laboratory parameters summarized in the form of the MELD score had significantly less descriptive correlation with the TACE outcome.
肝功能是经动脉化疗栓塞术(TACE)治疗结果的最重要参数之一。肝脏最大容量(LiMAx)试验是一种床边检测,可实时提供肝功能检测选项。本研究旨在探讨 LiMAX 试验对预测 TACE 结果的适用性。
20 例中期肝细胞癌(HCC)患者在 TACE 前和后 24 小时接受 LiMAx 试验。此外,还收集了实验室值以确定肝功能和终末期肝病模型(MELD)评分。TACE 后 6 周,通过使用改良实体瘤反应评价标准(mRECIST)的形态学成像检查评估 TACE 的疗效。
根据 mRECIST 评估,TACE 后客观缓解(OR=CR+PR)的患者的 LiMAx 试验预干预值显著高于 TACE 后无 OR(PD 或 SD)的患者(r(14)=0.62,p=0.01)。较高的预干预 LiMAx 值表明 OR。TACE 后根据 mRECIST 评估疾病控制(DC=CR+PR+SD)的患者的 LiMAx 试验预干预值显著高于 TACE 后非 DC(PD)的患者(r(14)=0.65,p=0.01)。较高的预干预 LiMAx 值表明 DC。TACE 前后 LiMAx 值与 OR 或 DC 的点二项相关,比 MELD 与 OR 或 DC 的点二项相关具有更强的描述性,这表明 LiMAx 试验与治疗反应的相关性优于 MELD 评分。
我们首次在研究中表明,计划接受 TACE 的患者可以从 LiMAx 试验中受益,以评估 TACE 的获益。预干预 LiMAx 值越高,TACE 的获益越大。另一方面,以 MELD 评分形式总结的实验室参数与 TACE 结果的描述性相关性显著降低。